Melanoma News and Research

Latest Melanoma News and Research

Free skin cancer screenings for local community

The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.

21 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Use of a simple, at-home screening test by Canadians can prevent many unnecessary colorectal cancer deaths, according to a special report about colorectal cancer in Canadian Cancer Statistics 2011 released today by the Canadian Cancer Society, in collaboration with the Public Health Agency of Canada and Statistics Canada.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

A new study links the intermittent interruption of breathing that occurs in patients with obstructive sleep apnea to enhanced proliferation of melanoma cancer cells and increased tumor growth in mice, according to researchers in Spain.

18 May 2011

Leucine deprivation triggers apoptosis in melanoma cells

Whitehead Institute researchers have found that depriving human melanoma cells of the essential amino acid leucine can be lethal to the cells, suggesting a possible strategy for therapeutic intervention.

18 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

IsoRay third fiscal quarter sales increase 17%

IsoRay Inc., announced financial results for the third fiscal quarter ended March 31, 2011 underscoring significant improvements in quarterly sales revenue growth both sequentially and in the prior year quarter. Sales increased 17% in the period with the Company posting a 581% gain in gross profit compared to the prior year third quarter.

16 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

Long non-coding RNA promotes melanoma cell survival and invasion

Traditionally, RNA was mostly known as the messenger molecule that carries protein-making instructions from a cell's nucleus to the cytoplasm. But scientists now estimate that approximately 97 percent of human RNA doesn't actually code for proteins at all. A flurry of research in the past decade has revealed that some types of non-coding RNAs switch genes on and off and influence protein function.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

Dermatologists to provide free melanoma screenings at Loyola Center for Health on May 20

During a free health fair at work that offered screenings for skin cancer, Joan Rojek decided on a whim to have a dermatologist examine some odd-looking blemishes on her arm.

10 May 2011

Skin cancer prevention tips for anglers

If you love fishing and want to enjoy it well into your senior years then don't mess around with the sun. That's the advice for the 1 million Minnesotans who are expected to hit the water on Saturday for Minnesota's Fishing Opener from a leading Edina plastic and reconstructive surgeon who has treated hundreds of patients over the course of his 15-year career for skin cancer and melanoma.

10 May 2011

When Government usurps responsibility, people are more likely to abdicate

We hear much talk about preventive care, but nobody has defined it. From the content of the discussions, I deduce that what the health bureaucrats actually refer to would be better characterized as “early detection.” Early detection is what occurs when a physician finds a disease in its early stages that might have been prevented by earlier measures. But who can take those measures? Not the physician, only the patient. There is only one person living the patient’s life; it is the patient. I cannot live his life for him.

9 May 2011

Melanoma News and Research

Latest Melanoma News and Research

Free skin cancer screenings for local community

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

Leucine deprivation triggers apoptosis in melanoma cells

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

IsoRay third fiscal quarter sales increase 17%

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Long non-coding RNA promotes melanoma cell survival and invasion

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Dermatologists to provide free melanoma screenings at Loyola Center for Health on May 20

Skin cancer prevention tips for anglers

When Government usurps responsibility, people are more likely to abdicate

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in